Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
In this multicenter, single‐arm, phase II study, the efficacy and safety of ibrutinib were examined in Japanese patients with relapsed or refractory mantle cell lymphoma (MCL). Patients (age ≥20 years) with relapsed or refractory MCL who had progressed after receiving at least one prior treatment re...
Main Authors: | Maruyama, Dai, Nagai, Hirokazu, Fukuhara, Noriko, Kitano, Toshiyuki, Ishikawa, Takayuki, Shibayama, Hirohiko, Choi, Ilseung, Hatake, Kiyohiko, Uchida, Toshiki, Nishikori, Momoko, Kinoshita, Tomohiro, Matsuno, Yoshihiro, Nishikawa, Tomoaki, Takahara, Satoko, Tobinai, Kensei |
---|---|
Format: | Online |
Language: | English |
Published: |
John Wiley and Sons Inc.
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198949/ |
Similar Items
-
Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
by: McNally, Gretchen Anne, et al.
Published: (2015) -
Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
by: Peterson, Derek, et al.
Published: (2014) -
Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
by: Ogura, Michinori, et al.
Published: (2013) -
Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
by: Ogura, Michinori, et al.
Published: (2014) -
Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma
by: Tamim Alsuliman, et al.
Published: (2018-01-01)